Table of contents
From the editors
p69 | doi:10.1038/nrc2086
Research Highlights
Angiogenesis: Less is more
p71 | doi:10.1038/nrc2076
Epigenetics: Early signs of trouble ahead
p72 | doi:10.1038/nrc2081
In the news
Cracking news
p72 | doi:10.1038/nrc2084
Metastasis: Breaking and entering
p73 | doi:10.1038/nrc2077
Tumorigenesis: A fishy tale of separation
p73 | doi:10.1038/nrc2079
Therapy: Foxing liver cancer
p74 | doi:10.1038/nrc2074
Trial Watch
Trial watch
p74 | doi:10.1038/nrc2083
Therapy: Escaping inhibition
p74 | doi:10.1038/nrc2085
Tumorigenesis: Jagged little pill?
p76 | doi:10.1038/nrc2075
Therapy: Restraint required
p76 | doi:10.1038/nrc2082
Genetics: Interconnected
p77 | doi:10.1038/nrc2078
Reviews
G-protein-coupled receptors and cancer
Robert T. Dorsam and J. Silvio Gutkind
p79 | doi:10.1038/nrc2069
G-protein-coupled receptors (GPCRs) influence many steps in tumorigenesis, including proliferation, survival, angiogenesis, metastasis and evasion of the immune system. This Review provides an overview of the various roles of GPCRs in cancer and their potential as therapeutic targets.
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero, Sandra Hervas-Stubbs, Martin Glennie, Drew M. Pardoll and Lieping Chen
p95 | doi:10.1038/nrc2051
Monoclonal antibodies (mAbs) that regulate the immune response are now being clinically evaluated as anticancer agents. This Review discusses their progress to date and the possibilities for combining these antibodies with other cancer treatments.
Targeted anti-mitotic therapies: can we improve on tubulin agents?
Jeffrey R. Jackson, Denis R. Patrick, Mohammed M. Dar and Pearl S. Huang
p107 | doi:10.1038/nrc2049
A new generation of promising anti-mitotic therapies that target proteins with specific functions in mitosis has been developed. As these drugs enter phase I and II trials, what do we know about their mechanism of action and their therapeutic range, and which patients will benefit?
Myelodysplastic syndromes: the complexity of stem-cell diseases
Seth J. Corey, Mark D. Minden, Dwayne L. Barber, Hagop Kantarjian, Jean C. Y. Wang and Aaron D. Schimmer
p118 | doi:10.1038/nrc2047
The term myelodysplastic syndromes covers various diseases that are caused by ineffective haematopoiesis in one or more lineages of the bone marrow. How do these diseases arise, and what are the best methods for treating these patients?
Perspectives
Opinion
Compressing drug development timelines in oncology using phase '0' trials
Shivaani Kummar, Robert Kinders, Larry Rubinstein, Ralph E. Parchment, Anthony J. Murgo, Jerry Collins, Oxana Pickeral, Jennifer Low, Seth M. Steinberg, Martin Gutierrez, Sherry Yang, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski and James H. Doroshow
p131 | doi:10.1038/nrc2066
The launch of phase '0' trials has generated much discussion in the cancer research community. This Perspective, written by scientists at the US National Cancer Institute, discusses the aims of these trials, gives some practical advice for conducting them and addresses several outstanding questions.
Article series: Tumour Microenvironment
Opinion
The tumour microenvironment as a target for chemoprevention
Adriana Albini and Michael B. Sporn
p139 | doi:10.1038/nrc2067
The microenvironment has a crucial role in cancer development, which suggests that microenvironmental targets should be investigated for chemoprevention. What are some of the potential targets and how might they be modulated?
Science and society
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes
Michele Carbone, Salih Emri, A. Umran Dogan, Ian Steele, Murat Tuncer, Harvey I. Pass and Y. Izzettin Baris
p147 | doi:10.1038/nrc2068
In Cappadocia, Turkey, a mesothelioma epidemic causes 50% of all deaths in three small villages. This manuscript reports, from a personal viewpoint, the scientific advances that have come from studying the families who have an inherited predisposition to develop this disease and the social problems that they face.
